Evidence map›Paper›PMID 24876922›Full record

ReviewWorld journal of radiology2014

Role of (18)F-FDG PET/CT in pre and post treatment evaluation in head and neck carcinoma.

Bundhit Tantiwongkosi, Fang Yu, Anand Kanard, Frank R Miller

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of radiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Article
  2. Role of [Cancer imaging : the official publication of the International Cancer Imaging Society · 2024
    Review
  3. Role ofCancers · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Plasma Metabolic Phenotypes of HPV-Associated versus Smoking-Associated Head and Neck Cancer and Patient Survival.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Bundhit TantiwongkosiBundhit Tantiwongkosi, Division of Neuroradiology, Department of Radiology and Otolaryngology Head Neck Surgery, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, United States.
Fang YuBundhit Tantiwongkosi, Division of Neuroradiology, Department of Radiology and Otolaryngology Head Neck Surgery, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, United States.
Anand KanardBundhit Tantiwongkosi, Division of Neuroradiology, Department of Radiology and Otolaryngology Head Neck Surgery, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, United States.
Frank R MillerBundhit Tantiwongkosi, Division of Neuroradiology, Department of Radiology and Otolaryngology Head Neck Surgery, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Head and neck cancer (HNC) ranks as the 6(th) most common cancer worldwide, with the vast majority being head and neck squamous cell carcinoma (HNSCC). The majority of patients present with complicated locally advanced disease (typically stage III and IV) requiring multidisciplinary treatment plans with combinations of surgery, radiation therapy and chemotherapy. Tumor staging is critical to decide therapeutic planning. Multiple challenges include accurate tumor localization with precise delineation of tumor volume, cervical lymph node staging, detection of distant metastasis as well as ruling out synchronous second primary tumors. Some patients present with cervical lymph node metastasis without obvious primary tumors on clinical examination or conventional cross sectional imaging. Treatment planning includes surgery, radiation, chemotherapy or combinations that could significantly alter the anatomy and physiology of this complex head and neck region, making assessment of treatment response and detection of residual/ recurrent tumor very difficult by clinical evaluation and computed tomography (CT) or magnetic resonance imaging (MRI). (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography/CT ((18)F-FDG PET/CT) has been widely used to assess HNC for more than a decade with high diagnostic accuracy especially in detection of initial distant metastasis and evaluation of treatment response. There are some limitations that are unique to PET/CT including artifacts, lower soft tissue contrast and resolution as compared to MRI, false positivity in post-treatment phase due to inflammation and granulation tissues, etc. The aim of this article is to review the roles of PET/CT in both pre and post treatment management of HNSCC including its limitations that radiologists must know. Accurate PET/CT interpretation is the crucial initial step that leads to appropriate tumor staging and treatment planning.

Indexed as

Computed tomographyHead and neck cancerPositron emission tomographyPost treatmentRecurrenceStaging

Identifiers

PMID24876922
PMCPMC4037544

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.